Results 21 to 30 of about 7,079 (242)

Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review [PDF]

Precision and Future Medicine, 2021
The development of treatment options has revolutionized the prognosis of inflammatory bowel disease (IBD). However, a particular group of patients still experience therapeutic failure or drug side effects.
Ji Young Chang, Jae Hee Cheon
doaj   +1 more source

gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease [PDF]

Intestinal Research, 2020
Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited by side effects such as leukopenia.
Katsuyoshi Matsuoka
doaj   +1 more source

Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]

PLoS ONE, 2015
Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu   +8 more
doaj   +1 more source

Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising “MINT” sequencing strategy and therapeutic “DNA-TG” monitoring

Frontiers in Pharmacology, 2022
Thiopurines, including thioguanine (TG), 6-mercaptopurine (6-MP), and azathioprine (AZA), are extensively used in clinical practice in children with acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases.
Hong-Li Guo, Yue-Tao Zhao, Yue-Tao Zhao, Wei-Jun Wang, Wei-Jun Wang, Na Dong, Na Dong, Ya-Hui Hu, Yuan-Yuan Zhang, Feng Chen, Li Zhou, Tao Li   +11 more
doaj   +1 more source

TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

BMC Gastroenterology, 2021
Background Polymorphisms in thiopurine methyltransferase (TPMT) and Nudix hydrolase-15 (NUDT15) have been implicated as the predominant cause of thiopurine induced leukopenia in the Western countries and East Asia respectively.
Narinder Grover, Prateek Bhatia, Antriksh Kumar, Minu Singh, Deepesh Lad, Harshal S. Mandavdhare, Jayanta Samanta, Kaushal K. Prasad, Usha Dutta, Vishal Sharma   +9 more
doaj   +1 more source

Azathioprine‐induced pancytopenia: A case report

Rheumatology & Autoimmunity, 2022
Azathioprine (AZA) is commonly used as immunosuppressive therapy for autoimmune diseases, including systemic lupus erythematosus (SLE). Myelosuppression is a common side effect of AZA.
Keshav Raj Sigdel, Astha Thapa, Agnimshwor Dahal, Ramchandra Panthi, Krishan Adhikari, Pradeep Shrestha, Mipsang Lama, Buddhi Poudyal, Buddha Basnyat   +8 more
doaj   +1 more source

LC–MS/MS Method for Measurement of Thiopurine Nucleotides (TN) in Erythrocytes and Association of TN Concentrations With TPMT Enzyme Activity

Frontiers in Pharmacology, 2022
Monitoring concentrations of thiopurine metabolites is used clinically to prevent adverse effects in patients on thiopurine drug therapy. We developed a LC–MS/MS method for the quantification of 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP) in ...
Amol O. Bajaj, Mark M. Kushnir, Mark M. Kushnir, Erik Kish-Trier, Rachel N. Law, Lauren M. Zuromski, Alejandro R. Molinelli, Gwendolyn A. McMillin, Gwendolyn A. McMillin, Kamisha L. Johnson-Davis, Kamisha L. Johnson-Davis   +10 more
doaj   +1 more source

6-thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party [PDF]

, 2006
Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004,
A. Teml, A.A. van Bodegraven, Al Hadithy AF, Artlich A, Bean RHD, Buffet C, C.J.J. Mulder, Carter MJ, Daniel F, De Boer N, de Boer NK, de Boer NK, de Jong D, Derijks LJ, Dervieux T, Dubinsky MC, Ferlitsch A, Fonseca V, Gane E, Gearry RB, H. Vogelsang, Haboubi NY, Herrlinger KR, Herrlinger KR, Herrlinger KR, J. Seiderer, Jones MC, K.R. Herrlinger, Katzka DA, Lilleyman JS, M. Lukas, M. Schwab, Marinaki AM, McBride KL, N.K.H. de Boer, Naber AH, P. Knoflach, Russmann S, Rutgeerts P, S. Almer, S.W. van der Merwe, Sandborn W, Schaeffeler E, Seiderer J, Shastri S, T. Ochsenkühn, Teml A, Teml A, Teml A, Tiede I, van Dieren JM, W. Petritsch, W. Reinisch   +52 more
core   +1 more source

A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population

BMC Research Notes, 2022
Objective The nucleoside diphosphate linked moiety X (Nudix)-Type motif 15 (NUDT15) enzyme is involved in thiopurine metabolism. Genetic variants in the NUDT15 gene result in decreased NUDT15 activity, which in addition to decreased thiopurine S ...
Kok-Siong Poon, Izz Irfan B. Imran, Silvester Kheng-Han Chew, Patrice Tan, Karen Mei-Ling Tan   +4 more
doaj   +1 more source

The fate of thiopurine metabolites after switching to low-dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis. [PDF]

Br J Clin Pharmacol
Aims Shunting (hypermethylating) thiopurine metabolism, characterized by excessive 6‐MMPR production and (sub)therapeutic 6‐TGN levels, poses a significant challenge in the treatment of inflammatory bowel disease (IBD). This study evaluates the metabolic outcomes of switching to low‐dose thiopurine with allopurinol (LDTA) or thioguanine (TG) in IBD ...
Bayoumy AB, D'Agnolo HMA, de Boer NKH, Mulder CJJ, Derijks LJJ.   +4 more
europepmc   +2 more sources